379270-36-7

Basic information

• Product Name: GS-7340 intermediate
• Synonyms: GS-7340 intermediate;L-Alanine, N-[[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester;(2R)-isopropyl 2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate;Tenofovir Alafenamide-d5 (diastereomers)
• CAS NO: 379270-36-7
• Molecular Formula: C21H29N6O5P
• Molecular Weight: 476.47
• EINECS: -0
• Mol File: 379270-36-7.mol
• Article Data: 39

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: GS-7340 intermediate(CAS DataBase Reference)
• NIST Chemistry Reference: GS-7340 intermediate(379270-36-7)
• EPA Substance Registry System: GS-7340 intermediate(379270-36-7)

Safety Data

• Hazardous Substances Data: 379270-36-7(Hazardous Substances Data)

Usage

Uses

Tenofovir Alafenamide-d5 is a labeled analog of Tenofovir Alafenamide. Tenofovir Alafenamide (T018555) is a prodrug of Tenofovir (T018500), which is a reverse transcriptase inhibitor used to treat HIV and Hepatitis B. Antiviral.

Upstream product

• 147127-20-6 tenofovir 
• 108-95-2 phenol 
• 39825-33-7 isopropyl L-alanine 
• 379270-35-6 ((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphoric acid monophenyl ester 
• 39613-92-8 alanine isopropyl ester hydrochloride 
• 383365-04-6 N-[(R)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphonyl]-L-alanine-1-methylethyl ester 
• 101-02-0 triphenyl phosphite 
• 2053424-88-5 (2S)-isopropyl2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate 
• 56-41-7 L-alanin 
• 79487-89-1 (R)-isopropyl 2-aminopropanoate 
• 39613-92-8 (R)-1-isopropoxy-1-oxopropan-2-aminium chloride 

Downstream Products

• 379270-37-8 (S)-isopropyl-2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate 
• 1392275-56-7 tenofovir alafenamide hemifumarate 
• 1392275-56-7 tenofovir alafenamide fumarate 

Relevant articles and documents

Method for preparing antiviral drug tenofovir alafenamide fumarate

The invention discloses a method for preparing an antiviral drug tenofovir alafenamide fumarate, which comprises the following steps of: (1) reacting adenine with (R)-propylene carbonate to generate a compound I; (2) treating the compound I with magnesium tert-butoxide, and then adding phosphonate S to react to obtain a compound II; (3) the compound III is obtained by hydrolyzing the compound II in hydrobromic acid; (4) reacting the compound III with thionyl chloride to obtain phosphonyl chloride, and directly reacting the phosphonyl chloride with L-alanine isopropyl ester without purification to generate a compound IV; and (5) obtaining a final product, wherein the preparation of the propionyl phenol fumarate tenofovir is completed by salifying the compound IV and fumaric acid. The method has the advantages of few synthetic route steps, mild reaction conditions and principle saving, and can improve the yield of the final product.

Preparation method of intermediate GS103 of tenofovir prodrug

The invention relates to a preparation method of an intermediate GS103 of a tenofovir prodrug. A product obtained by the method is good in purity and high in yield.

NRTI THERAPIES

Polymer-of-prodrug (POP) materials enable new nucleoside reverse transcriptase inhibitor (NRTI) therapy strategies. The materials are prodrugs of NRTIs in the form of polymers. Suitable materials include products which are polymeric NRTI delivery systems comprising polymeric materials which are capable of degradation after administration to release NRTIs or NRTI prodrugs which themselves are capable of metabolism to the parent NRTIs. The NRTIs may optionally be selected from tenofovir (TFV), emtricitabine (FTC), lamivudine (3TC) and MK-8591 (EFdA). The invention facilitates long-acting (LA) regimens. Constructs of the materials may be in the form of injectable compositions or implants.